Search results
Results From The WOW.Com Content Network
The total cost to Novartis for the 77% stake in Alcon was $38.7 billion ($168 per share). In the deal's first phase, Novartis acquired a 25% stake in Alcon from Nestlé for $10.4 billion in July 2008.
On July 8, 2010, Alcon's independent director committee (IDC) had set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG. On April 9, 2019, Alcon completed a 100% spin-off from Novartis. The new standalone company is worth up to 28 billion Swiss francs. In November 2021, Alcon ...
Contract bridge, or simply bridge, is a trick-taking card game using a standard 52-card deck. In its basic format, it is played by four players in two competing partnerships, [1] with partners sitting opposite each other around a table. [a] Millions of people play bridge worldwide in clubs, tournaments, online and with friends at home, making ...
hand card. A card held in the hand as opposed to one on the table. hand game or handplay. A type of contract in certain games in which the skat or widow is not used. See Hand game (cards). [64] hard score. A game played for 'hard score' – as opposed to those played for soft score – is one played for money.
Shares of Novartis (NVS) soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon (ACL) for $12.9 billion. Novartis had been trying to gain ...
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Opening lead. The opening lead is the first card played in the playing phase of a contract bridge deal. The defender sitting to the left (LHO) of the declarer is the one who makes the opening lead. Since it is the only card played while dummy's cards are still concealed, it can be critical for the outcome of the deal.
Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.